Cannabis abuse and the course of schizophrenia
Don H. Linszen, Bart D. Peters, Lieuwe de Haan
Cambridge University Press eBooks May 27, 2004 DOI: 10.1017/cbo9780511543630.010 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Cannabis |
| Citations | 9 |
| Key findings | The chapter argues that cannabis, especially in high doses, can produce a toxic psychosis in people without mental disorders, and that evidence from cohort and epidemiological studies (Swedish and Israeli conscripts, the Dunedin study, and a Dutch sample) supports heavy cannabis use as a causal risk factor for psychotic disorders. It also describes schizophrenia as having three symptom dimensions: reality distortion, psychomotor poverty, and disorganization. |
Abstract
As detailed elsewhere in this book (Chapter 3), cannabis has been used for centuries to produce euphoria and relaxation as desired mental effects. However, adverse effects of intoxication with cannabis include anxiety and panic (Thomas, 1996; Reilly et al. , 1998), depression (Bovasso, 2001; Patton et al. , 2002: see Chapter 4), and impairment in certain domains of cognitive function (see Chapters 3 and 13). Psychosis, including paranoid delusions and hallucinations, has been found to be an effect of cannabis use in cohort studies from New Zealand (Thomas, 1996), Vietnam (Talbott and Teague, 1969), India (Chopra and Smith, 1974) and Pakistan (Chaudry et al. , 1991) (Chapter 6). This work suggests that cannabis, especially in high doses, can produce a toxic psychosis in people without mental disorders. Evidence for cannabis (and especially heavy abuse) as a causal risk factor for psychotic disorders comes from epidemiological studies of Swedish conscripts (Andreasson et al. , 1987; Zammit et al. , 2002), from the Dunedin study from New Zealand (Arsenault et al. , 2002), from a Dutch sample (Van Os et al. , 2002) and from a study of Israeli conscripts (Weiser et al. , 2001) (see Chapter 7). Schizophrenia and related psychotic disorders are clinical syndromes with a wide variation in symptoms between individuals (Thaker and Carpenter, 2001). Factor-analytic studies of schizophrenia have revealed that the symptoms are best described by three dimensions or syndromes: reality distortion (hallucinations and delusions), psychomotor poverty (restriction of affect, loss of motivation and restricted emotional experience) and disorganization (disorganized thought, incongruity of affect and bizarre behaviour) (Liddle, 1987).
Comparable studies
Other narrative reviews on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Causal association between cannabis and psychosis: examination of the evidence | 2004 | Review | |
| Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. General (historical and pharmacological review) | 2018 | Review | |
| Psychiatric effects of cannabis | 2001 | Review | |
| Beyond THC: The New Generation of Cannabinoid Designer Drugs | 2011 | Review | |
| Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | 2006 | Review |
Citations in the library
Cited by 2
Cites 4
- Cannabis use and outcome of recent onset psychosis European Psychiatry June 1, 2005
- Cannabis use and psychosis: a review of clinical and epidemiological evidence. Australian & New Zealand Journal of Psychiatry February 1, 2000
- Cannabis consumption as a prognostic factor in schizophrenia. The British Journal of Psychiatry May 1994
- Cannabis psychosis following bhang ingestion. British Journal of Addiction September 1, 1991